Investigational drug · Phase 2
Flu mRNA
Also called: GSK6479720A, GSK6498032A, GSK6479715A
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Influenza, Human.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
65
Any phase or sponsor naming "Flu mRNA"
First trial start
2025
Aug 25, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Flu mRNA", any sponsor or status.
Conditions studied
As listed on its trial records.
- Influenza, Human
Approved drugs for the same conditions: Influenza · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "Flu mRNA" as an intervention, largest first.
ModernaTX, Inc.Moderna (MRNA)
NCT06130345 · 15,196,685 participants · Start Apr 14, 2023 · Primary completion Feb 29, 2024
Drug: SPIKEVAX · For: SARS-CoV-2
Sites: New York, New York
PfizerPfizer (PFE)
NCT05858450 · 3,442,996 participants · Start May 5, 2023 · Primary completion May 12, 2023
Drug: Comirnaty; Quadrivalent Influenza Vaccine · For: Influenza, Human; COVID-19
Sites: New York, New York
- Effectiveness of An Influenza/COVID-19 Vaccine (mCombriax [mRNA-1083]) in Adults ≥ 65 YearsPivotal-lookingNot yet recruiting
Tor Biering-SørensenAcademic, hospital or other
NCT07790523 · 410,000 participants (planned) · Start Sep 1, 2026 · Primary completion May 31, 2028
Drug: mCombriax® (mRNA-1083); Efluelda® (TIV-HD) and Spikevax® (mRNA-1273) · For: COVID-19; Influenza
Sites: Hellerup, Denmark; Søborg, Denmark; Santiago de Compostela, Spain
- A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and OlderPivotal-lookingCompleted
ModernaTX, Inc.Moderna (MRNA)
NCT05566639 · 22,502 participants · Start Sep 14, 2022 · Primary completion Jan 5, 2024
Drug: mRNA-1010; Fluarix Quadrivalent · For: Seasonal Influenza
Sites: Athens, Alabama; Glendale, Arizona; Phoenix, Arizona · 233 sites in all
- Study of mRNA-1010 Seasonal Influenza Vaccine in AdultsPivotal-lookingCompleted
ModernaTX, Inc.Moderna (MRNA)
NCT05827978 · 8,411 participants · Start Apr 17, 2023 · Primary completion Jun 24, 2024
Drug: mRNA-1010; Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine · For: Seasonal Influenza
Sites: Anniston, Alabama; Athens, Alabama; Cullman, Alabama · 103 sites in all
Fondazione Policlinico Universitario Agostino Gemelli IRCCSAcademic, hospital or other
NCT05781191 · 8,231 participants · Start Nov 13, 2021 · Primary completion Dec 31, 2021
Drug: COMIRNATY · For: Influenza; COVID-19
Sites: Roma, Italy
- A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of AgePivotal-lookingCompleted
ModernaTX, Inc.Moderna (MRNA)
NCT06097273 · 8,061 participants · Start Oct 19, 2023 · Primary completion May 28, 2024
Drug: mRNA-1083; Placebo and 2 more · For: SARS-CoV-2; Influenza
Sites: Anniston, Alabama; Birmingham, Alabama; Cullman, Alabama · 146 sites in all
- A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of AgePivotal-lookingCompleted
ModernaTX, Inc.Moderna (MRNA)
NCT05330975 · 3,317 participants · Start Apr 1, 2022 · Primary completion Nov 8, 2024
Drug: Placebo; mRNA-1345 and 2 more · For: Respiratory Syncytial Virus
Sites: Birmingham, Alabama; Tucson, Arizona; Garden Grove, California · 62 sites in all
- A Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in Adults 18-64 Years of AgePivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07851246 · 3,000 participants (planned) · Start Oct 1, 2026 · Primary completion Jul 9, 2027
Drug: mRNA Seasonal Flu vaccine; Comparator 1 and 1 more · For: Influenza, Human
Sites: Glendale, Arizona; Tucson, Arizona; San Diego, California · 12 sites in all
- Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of AgePivotal-lookingCompleted
ModernaTX, Inc.Moderna (MRNA)
NCT06694389 · 2,457 participants · Start Nov 18, 2024 · Primary completion Nov 17, 2025
Drug: mRNA-1083; Licensed Influenza Vaccine and 1 more · For: COVID-19; Influenza
Sites: Nagoya, Japan; Fukuoka, Japan; Sapporo, Japan · 44 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Influenza, Human
- GP681Phase 32 trials
Jiangxi Qingfeng Pharmaceutical Co. Ltd. · Influenza, Human, Influenza
- GP681 SimulantPhase 32 trials
Jiangxi Qingfeng Pharmaceutical Co. Ltd. · Influenza, Human, Influenza
- ARCT-2304Phase 21 trial
Arcturus Therapeutics, Inc. · Influenza, Human
- DL001ZF2G22B, F2H23HPhase 21 trial
GSK · Influenza, Human
- DL001Z-NHF2H23D, F2H23BPhase 21 trial
GSK · Influenza, Human
- GSK5800544APhase 21 trial
GSK · Influenza, Human
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from GSK.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.